Abstract:Transcriptionally latent forms of replication-competent proviruses, present primarily in a small subset of memory CD4 + T cells, pose the primary barrier to a cure for HIV-1 infection because they are the source of the viral rebound that almost inevitably follows the interruption of antiretroviral therapy. Over the last 30 years, many of the factors essential for initiating HIV-1 transcription have been identified in studies performed using transformed cell lines, such as the Jurkat T-cell model. However, as highlighted in this review, several poorly understood mechanisms still need to be elucidated, including the molecular basis for promoter-proximal pausing of the transcribing complex and the detailed mechanism of the delivery of P-TEFb from 7SK snRNP. Furthermore, the central paradox of HIV-1 transcription remains unsolved: how are the initial rounds of transcription achieved in the absence of Tat? A critical limitation of the transformed cell models is that they do not recapitulate the transitions between active effector cells and quiescent memory T cells. Therefore, investigation of the molecular mechanisms of HIV-1 latency reversal and LRA efficacy in a proper physiological context requires the utilization of primary cell models. Recent mechanistic studies of HIV-1 transcription using latently infected cells recovered from donors and ex vivo cellular models of viral latency have demonstrated that the primary blocks to HIV-1 transcription in memory CD4 + T cells are restrictive epigenetic features at the proviral promoter, the cytoplasmic sequestration of key transcription initiation factors such as NFAT and NF-κB, and the vanishingly low expression of the cellular transcription elongation factor P-TEFb. One of the foremost schemes to eliminate the residual reservoir is to deliberately reactivate latent HIV-1 proviruses to enable clearance of persisting latently infected cells—the "Shock and Kill" strategy. For "Shock and Kill" to become efficient, effective, non-toxic latency-reversing agents (LRAs) must be discovered. Since multiple restrictions limit viral reactivation in primary cells, understanding the T-cell signaling mechanisms that are essential for stimulating P-TEFb biogenesis, initiation factor activation, and reversing the proviral epigenetic restrictions have become a prerequisite for the development of more effective LRAs.

Quercetin Synergistically Reactivates Human Immunodeficiency Virus Type 1 Latency by Activating Nuclear Factor‑κb.

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

Dilazep Synergistically Reactivates Latent HIV-1 in Latently Infected Cells.

Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodies

Reactivation of latent HIV-1 in latently infected cells by coumarin compounds: Hymecromone and ScoparoneReactivation of Latent HIV-1 in Latently Infected Cells by Coumarin Compounds: Hymecromone and Scoparone

Dilazep Synergistically Reactivates Latent HIV-1 in Latently Infected Cells Hanxian ZengSijie LiuPengfei WangXiying QuHaiyan Ji • Xiaohui WangXiaoli ZhuZhishuo SongXinyi YangZhongjun Ma •

Scopoletin Reactivates Latent HIV-1 by Inducing NF-?B Expression without Global T Cell Activation

Scopoletin Reactivates Latent HIV-1 by Inducing NF-κB Expression without Global T Cell Activation

Small-molecule Screening Using a Human Primary Cell Model of HIV Latency Identifies Compounds That Reverse Latency Without Cellular Activation.

A Natural Product From Polygonum Cuspidatum Sieb. Et Zucc. Promotes Tat-Dependent Hiv Latency Reversal Through Triggering P-Tefb'S Release From 7sk Snrnp

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency

KDM5A/B promotes HIV-1 latency and KDM5 inhibitors promote HIV-1 lytic reactivation

Specific Reactivation of Latent HIV-1 with Designer Zinc-Finger Transcription Factors Targeting the HIV-1 5′-LTR Promoter

Histone deacetylase inhibitor MC1293 induces latent HIV-1 reactivation by histone modification in vitro latency cell lines.

HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells.

Oxaliplatin Antagonizes HIV-1 Latency by Activating NF-κB Without Causing Global T Cell Activation.

The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb

The cell biology of HIV-1 latency and rebound